Heron Therapeutics
HRTX
186 hedge funds and large institutions have $621M invested in Heron Therapeutics in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 75 increasing their positions, 47 reducing their positions, and 36 closing their positions.
202% more call options, than puts
Call options by funds: $7.75M | Put options by funds: $2.57M
60% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 47
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 200 → 186 (-14)
9.13% less ownership
Funds ownership: 115.41% → 106.28% (-9.1%)
39% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 36
42% less capital invested
Capital invested by funds: $1.07B → $621M (-$453M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$38.3M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$9.23M |
| 3 |
Morgan Stanley
New York
|
+$8.62M |
| 4 |
D.E. Shaw & Co
New York
|
+$5M |
| 5 |
OCM
Orchard Capital Management
Chicago,
Illinois
|
+$4.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$75.6M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
-$29.7M |
| 3 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$21.4M |
| 4 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$12.6M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$10.8M |
HRTX Hedge Fund Activity: Q1 2022 in Review
186 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q1 2022, worth a combined $621M — down 42% from $1.07B a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of HRTX and 22 opened new positions — a net loss of 14 holders — while 47 trimmed existing stakes and 75 added.
The largest buyer was State Street, adding an estimated $38.3M. The largest seller was UBS O'Connor, exiting entirely with an estimated $75.6M sold.
- 186 institutional investors held Heron Therapeutics (HRTX) as of Q1 2022, down from 200 in Q4 2021.
- Funds reported $621M of Heron Therapeutics stock for Q1 2022, down 42% quarter-over-quarter.
- 22 funds opened new Heron Therapeutics positions in Q1 2022 and 36 closed out, a net change of -14 holders.
- The largest Heron Therapeutics buyer in Q1 2022 was State Street, an estimated $38.3M added.
- The largest Heron Therapeutics seller in Q1 2022 was UBS O'Connor, an estimated $75.6M sold.
Based on aggregated 13F filings for Q1 2022.